Research
Hormonal
Asprosin promotes hepatic glucose production (gluconeogenesis) and stimulates appetite (orexigenic effect) via central and peripheral signaling pathways, although the reproducibility of these effects is controversial due to reagent quality issues.
Research suggests asprosin might increase hunger and liver glucose output, but studies are inconsistent. Some early positive findings may have been due to experimental errors. Until the science is settled, focus on proven methods for managing hunger and blood sugar like balanced nutrition and exercise.
LimitedQualifiesLOW confidence
Asprosin plays a complex role in the central nervous system (CNS), peripheral tissues, and organs. It is involved in appetite, glucose metabolism... The central receptors of asprosin are mainly located in the hypothalamic arcuate nucleus, contributing to promoting appetite... In the liver, the main target organs and tissues are the liver... leads to the production and release of glucose
Why this rating
Original studies show effects, but replication studies fail to confirm them, citing reagent quality.
Source
Asprosin: A Novel Player in Metabolic Diseases
Mingyang Yuan et al. · Frontiers in Endocrinology · 2020
DOI 10.3389/fendo.2020.00064
narrative_reviewCited 169×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Elevated circulating asprosin levels are positively associated with insulin resistance, type 2 diabetes, and obesity in adult populations, suggesting asprosin acts as a biomarker for metabolic dysregulation.Moderate
- Asprosin may have a protective role in cardiovascular disease by preventing cardiomyocyte apoptosis and improving mesenchymal stromal cell function in myocardial infarction models.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →